The immune system's window of weakness after severe COVID-19
In the long aftermath of the pandemic, a large Chilean study has surfaced a sobering entanglement between two ancient adversaries of human health: severe COVID-19 and tuberculosis. Among 3.6 million adults tracked over two years, those hospitalized with the virus faced nearly nine times the risk of developing TB within the following year — a finding that suggests the body's most violent encounters with COVID-19 may leave immunological wounds that outlast the illness itself. The research, published in Nature Communications, adds a quieter chapter to the pandemic's toll, one written not in acute crisis but in the slow vulnerabilities that follow, and it calls on health systems to look after survivors long after the fever breaks.
- A cohort of 3.6 million Chilean adults has revealed that severe COVID-19 hospitalization is associated with an eightfold to ninefold spike in tuberculosis risk — a magnitude that demands clinical attention.
- The danger is front-loaded: more than a third of new TB cases appeared within two months of COVID-19 diagnosis, and the association nearly doubled when researchers focused solely on the first six months.
- Vulnerability was not evenly shared — men, migrants, diabetics, and those relying on public healthcare bore disproportionate risk, while unvaccinated survivors showed the sharpest COVID-TB link of all.
- Vaccination before infection appeared to blunt the association substantially, though researchers stopped short of calling it direct TB protection, and questions linger about whether corticosteroid treatment may inadvertently widen the window of immune suppression.
- With 733 new TB cases identified and global TB burden already at 10.7 million active cases annually, researchers are urging targeted screening for severe COVID-19 survivors — especially those with comorbidities — as a concrete, actionable response.
A study tracking 3.6 million Chilean adults has found that surviving a severe case of COVID-19 may leave the immune system compromised in ways that dramatically raise the risk of tuberculosis. People who required hospitalization faced roughly nine times the TB risk of those with mild infections — a pattern that persisted for a year but was most concentrated in the first six months, when more than a third of new cases emerged.
The cohort spanned March 2020 to October 2022 and excluded anyone with pre-existing TB or serious immunocompromising conditions. Most participants — 94 percent — experienced mild illness. But among the smaller fraction admitted to hospital or intensive care, the hazard ratios for new TB hovered between 8.3 and 8.9. In total, 733 people developed active tuberculosis, with a median of 127 days between their COVID-19 diagnosis and TB onset.
Risk was unevenly distributed. Men, migrants, people with diabetes or chronic lung disease, and those enrolled in Chile's public health system faced higher odds. The biological explanation likely involves the hyperinflammatory response of severe COVID-19, which can damage lung tissue and create a temporary window of immunosuppression — enough to reactivate dormant TB bacteria or increase susceptibility to new infection.
Vaccination status proved to be a meaningful variable. Unvaccinated individuals who experienced severe COVID-19 showed the strongest TB association, while those who had completed their vaccine series before infection saw the link substantially reduced. The authors also noted that the association appeared stronger after corticosteroids became standard treatment for severe COVID-19, raising questions — though not conclusions — about whether certain interventions might inadvertently affect TB risk.
The researchers call for targeted TB screening among severe COVID-19 survivors, particularly those with comorbidities or without prior vaccination. The finding arrives against a backdrop of global TB burden already strained by pandemic disruptions, including an estimated 500,000 excess TB deaths between 2020 and 2022. It is a reminder that the pandemic's consequences extend well beyond the acute phase — and that some of its most consequential chapters are still being written.
A study of 3.6 million Chilean adults has found that people hospitalized with severe COVID-19 face roughly nine times the risk of developing tuberculosis within a year compared to those with milder infections. The finding, published in Nature Communications, suggests that the virus's most serious form may compromise the immune system in ways that persist long after the acute illness passes, leaving survivors vulnerable to a disease that has killed more than a million people globally each year.
Researchers tracked adults who tested positive for COVID-19 between March 2020 and October 2022, excluding those with pre-existing tuberculosis or severe immunocompromising conditions. The cohort was roughly evenly split between men and women, with a median age of 40. Most—94 percent—experienced mild enough illness to avoid hospitalization. But among the 2.8 percent who required hospital admission and the 3.1 percent admitted to intensive care, the pattern was stark: both groups showed hazard ratios around 8.3 to 8.9 for new tuberculosis cases. Over the follow-up period, 733 people developed active TB, though this represented just 0.02 percent of the total cohort. The median time from COVID-19 diagnosis to TB onset was 127 days, with more than a third of cases appearing within two months.
The risk was not uniform across the population. Men, migrants, people enrolled in Chile's public healthcare system, and those with major chronic conditions like diabetes or lung disease faced higher odds. Older adults showed somewhat lower relative risk than younger survivors, though absolute numbers were small in both groups. The excess risk declined over time but remained elevated even a year out, suggesting that severe COVID-19 may cause lasting damage to lung tissue or immune function. When researchers narrowed their focus to just the first six months, the association nearly doubled in magnitude, indicating that the window of heightened vulnerability is concentrated early.
Vaccination status emerged as a crucial modifier. Among unvaccinated individuals who experienced severe COVID-19, the TB risk spike was pronounced. But in those who had completed their vaccination series before infection, the association was substantially blunted—though researchers cautioned against interpreting this as direct TB prevention. Only 16.5 percent of the entire cohort had finished vaccination before their COVID-19 diagnosis, reflecting the timeline of the study period. The authors noted that the stronger association observed after corticosteroids became standard treatment for severe COVID-19 raises questions about whether certain interventions might inadvertently increase TB risk, though the study's design cannot prove individual treatment effects.
The biological mechanism likely involves the hyperinflammatory response that characterizes severe COVID-19. This intense immune activation can damage lung tissue and create a window of transient immunosuppression—a state in which the body's defenses are temporarily weakened. For people carrying dormant tuberculosis bacteria, this window can allow reactivation. For others, it may increase susceptibility to new infection. The study cannot prove causation, only association, and the absolute number of TB cases remained low. But the finding carries weight given the global TB burden: roughly 10.7 million people worldwide had active TB in 2024, and the pandemic itself disrupted TB control efforts so severely that an estimated 500,000 excess deaths occurred between 2020 and 2022.
The researchers recommend targeted screening for latent and active tuberculosis among survivors of severe COVID-19, particularly those with comorbidities or without prior vaccination. Such screening could identify cases early, when treatment is most effective. The study suggests that the acute and post-acute phases of severe COVID-19 may impair both lung integrity and immune function in ways that warrant clinical attention beyond the immediate recovery period. For public health systems already strained by pandemic disruptions, the finding underscores the need to rebuild TB surveillance and treatment capacity while remaining alert to new vulnerabilities emerging from COVID-19 survivors.
Notable Quotes
Severe COVID-19 was associated with a higher risk of incident TB within 1 year than non-severe COVID-19, although the observational design cannot establish causality, and the absolute incidence of TB was low.— Study authors, Nature Communications
Targeted screening for latent TB infection and active TB disease among survivors of severe COVID-19, particularly those with comorbidities such as diabetes or without prior SARS-CoV-2 vaccination, may help alleviate the TB burden.— Study authors, Nature Communications
The Hearth Conversation Another angle on the story
Why would a respiratory virus like COVID-19 specifically increase TB risk? They're both lung infections, but the mechanism seems indirect.
It's not about the virus directly causing TB. It's about what severe COVID-19 does to the immune system. The body mounts this intense, chaotic inflammatory response to fight the virus—and that response can damage lung tissue and create a temporary window where immunity is weakened. If someone's carrying dormant TB bacteria, that window is when reactivation happens.
So it's not that COVID-19 makes you more likely to catch TB from someone else?
It could be both. The study can't distinguish between reactivation of old infection and new acquisition. But the timing matters—most cases appeared within two months, which fits the reactivation pattern better. And the risk was highest in unvaccinated people, which suggests vaccination somehow protected that immune window.
The study says vaccination "appears protective" but warns against interpreting it as TB prevention. Why the caution?
Because this is observational data. Vaccinated people might have been healthier overall, or more likely to seek medical care, or lived in different conditions. The study can't isolate vaccination as the cause of lower TB risk. It just shows the association is weaker in vaccinated groups.
Who suffered most? The numbers show 733 cases out of 3.6 million, but that's not random.
Men, migrants, people in the public health system, and those with existing conditions like diabetes. These are populations that often face barriers to healthcare and live with chronic stress. Severe COVID-19 hit them harder to begin with, and the TB risk followed the same fault lines.
What happens now? Is there a clinical protocol?
The authors are calling for targeted TB screening in severe COVID survivors, especially those without vaccination or with comorbidities. It's preventive medicine—catch latent TB before it becomes active, or catch active disease early. But it requires resources and coordination that many health systems are still rebuilding after the pandemic.